Dr. Reddy’s Laboratories announced the launch of Ropinirole HCl Extended-Release (XR) tablets, the generic version of GlaxoSmithKline‘s Requip XL tablets.

Requip XL is an orally administered, non-ergoline dopamine agonist indicated for the treatment of the signs and symptoms idiopathic Parkinson’s disease. The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.

Ropinirole HCl XR will be available in 2mg, 4mg, 6mg strength tablets in 30- and 90-count bottles, and 8mg and 12mg strength tablets in 30-count bottles.

For more information call (908) 203-4933 or visit www.drreddys.com